These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12749433)

  • 1. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.
    Azziz R; Ehrmann DA; Legro RS; Fereshetian AG; O'Keefe M; Ghazzi MN;
    Fertil Steril; 2003 Apr; 79(4):932-7. PubMed ID: 12749433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
    Azziz R; Ehrmann D; Legro RS; Whitcomb RW; Hanley R; Fereshetian AG; O'Keefe M; Ghazzi MN;
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1626-32. PubMed ID: 11297595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
    Dunaif A; Scott D; Finegood D; Quintana B; Whitcomb R
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3299-306. PubMed ID: 8784087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
    Paradisi G; Steinberg HO; Shepard MK; Hook G; Baron AD
    J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
    Ehrmann DA; Schneider DJ; Sobel BE; Cavaghan MK; Imperial J; Rosenfield RL; Polonsky KS
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2108-16. PubMed ID: 9215280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
    Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
    Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
    Sathyapalan T; Smith KA; Coady AM; Kilpatrick ES; Atkin SL
    Ann Clin Biochem; 2012 Jan; 49(Pt 1):80-5. PubMed ID: 21972424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.
    Hasegawa I; Murakawa H; Suzuki M; Yamamoto Y; Kurabayashi T; Tanaka K
    Fertil Steril; 1999 Feb; 71(2):323-7. PubMed ID: 9988406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin concentrations in the polycystic ovary syndrome.
    Mantzoros CS; Dunaif A; Flier JS
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1687-91. PubMed ID: 9177364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
    Kolodziejczyk B; Duleba AJ; Spaczynski RZ; Pawelczyk L
    Fertil Steril; 2000 Jun; 73(6):1149-54. PubMed ID: 10856473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats.
    Min KM; Park SW; Cho KY; Song MS; Kim DK; Park GS; Lee MK
    Metabolism; 2002 Aug; 51(8):998-1002. PubMed ID: 12145772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Troglitazone for treatment of polycystic ovary syndrome].
    Sanaka M; Iwamoto Y
    Nihon Rinsho; 2000 Feb; 58(2):465-70. PubMed ID: 10707578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome.
    Kjøtrød SB; Sunde A; von Düring V; Carlsen SM
    Fertil Steril; 2009 Feb; 91(2):500-8. PubMed ID: 18304542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects of Troglitazone in patients with diet-controlled type 2 diabetes.
    Robinson AC; Jeffs JA; Gray RG; Bannister PA; Mather H; Gallagher JJ; Robinson S; Nattrass M; Venkatesan S; Halliday D; Johnston DG
    Eur J Clin Invest; 2004 Jan; 34(1):29-36. PubMed ID: 14984435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.
    Ghazeeri G; Kutteh WH; Bryer-Ash M; Haas D; Ke RW
    Fertil Steril; 2003 Mar; 79(3):562-6. PubMed ID: 12620440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
    Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome.
    Kauffman RP; Baker VM; DiMarino P; Castracane VD
    Fertil Steril; 2006 Apr; 85(4):1010-6. PubMed ID: 16580388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.
    Romualdi D; Giuliani M; Draisci G; Costantini B; Cristello F; Lanzone A; Guido M
    Fertil Steril; 2007 Jul; 88(1):131-8. PubMed ID: 17336978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.